HomeCompareRECEF vs CL

RECEF vs CL: Dividend Comparison 2026

RECEF yields 909.09% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RECEF wins by $8252648.17M in total portfolio value
10 years
RECEF
RECEF
● Live price
909.09%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8252648.21M
Annual income
$6,784,560,004,057.53
Full RECEF calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — RECEF vs CL

📍 RECEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRECEFCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RECEF + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RECEF pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RECEF
Annual income on $10K today (after 15% tax)
$77,272.73/yr
After 10yr DRIP, annual income (after tax)
$5,766,876,003,448.90/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, RECEF beats the other by $5,766,875,998,857.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RECEF + CL for your $10,000?

RECEF: 50%CL: 50%
100% CL50/50100% RECEF
Portfolio after 10yr
$4126324.13M
Annual income
$3,392,280,004,729.75/yr
Blended yield
82.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

RECEF
No analyst data
Altman Z
-148.3
Piotroski
1/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RECEF buys
0
CL buys
0
No recent congressional trades found for RECEF or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRECEFCL
Forward yield909.09%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$8252648.21M$40.8K
Annual income after 10y$6,784,560,004,057.53$5,401.96
Total dividends collected$8138900.96M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: RECEF vs CL ($10,000, DRIP)

YearRECEF PortfolioRECEF Income/yrCL PortfolioCL Income/yrGap
1← crossover$101,609$90,909.09$11,012$312.01+$90.6KRECEF
2$972,011$863,288.79$12,196$412.95+$959.8KRECEF
3$8,758,157$7,718,105.75$13,599$549.66+$8.74MRECEF
4$74,364,546$64,993,317.91$15,288$736.64+$74.35MRECEF
5$595,318,755$515,748,691.06$17,353$995.28+$595.30MRECEF
6$4,495,664,203$3,858,673,134.79$19,926$1,357.80+$4495.64MRECEF
7$32,043,550,537$27,233,189,840.42$23,194$1,873.82+$32043.53MRECEF
8$215,696,715,677$181,410,116,602.38$27,439$2,621.52+$215696.69MRECEF
9$1,372,045,052,584$1,141,249,566,809.58$33,088$3,727.38+$1372045.02MRECEF
10$8,252,648,210,323$6,784,560,004,057.53$40,806$5,401.96+$8252648.17MRECEF

RECEF vs CL: Complete Analysis 2026

RECEFStock

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Full RECEF Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this RECEF vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RECEF vs SCHDRECEF vs JEPIRECEF vs ORECEF vs KORECEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.